Source comparison
The Unvarnished Truth About MK-677 vs HGH Efficacy Claims
Here's the honest answer: MK-677 is not 'oral HGH'. The marketing that frames it as a pill-form replacement for injections is biochemically inaccurate. It's a secretagogue, not a hormone. The mechanism is fundamentally different, the IGF-1 ceiling is lower, an
This comparison does not assign a generated winner or score.
- Here's the honest answer: MK-677 is not 'oral HGH'. The marketing that frames it as a pill-form replacement for injections is biochemically inaccurate. It's a secretagogue, not a hormone. The mechanism is fundamentally different, the IGF-1 ceiling is lower, and the applications are non-overlapping in many cases. If your research question requires IGF-1 levels above 150% baseline, MK-677 won't get you there no matter how high you dose it. The ghrelin receptor pathway has a physiological ceiling. You can't force the pituitary to release more GH than its somatotroph population can synthesize, and that ceiling is roughly 90–100% above baseline even with maximal receptor stimulation.
- What MK-677 does offer is preservation of the endocrine axis. That's not a consolation prize. It's a distinct advantage for protocols where post-cycle recovery, pulsatile signaling, or long-term sustainability matter more than peak IGF-1 saturation. Exogenous HGH is pharmacologically more potent in absolute terms, but potency without regard for feedback suppression creates downstream costs that secretagogues don't. The choice isn't 'which is better'. It's 'which mechanism answers the research question.' We've seen institutions waste months trying to use MK-677 in studies that required HGH-level IGF-1 elevation, and we've seen the inverse: researchers using HGH in aging models where pulsatility preservation was the entire point. Neither compound is a universal tool.